prostatic adenocarcinoma

Related by string. * Prostatic : benign prostatic hyperplasia BPH . Benign prostatic hyperplasia BPH . Benign Prostatic Hyperplasia BPH . benign prostatic hypertrophy BPH . prostatic intraepithelial neoplasia / adenocarcinomas . Adenocarcinoma : pancreatic ductal adenocarcinoma . esophageal adenocarcinoma . adenocarcinoma histology . oesophageal adenocarcinoma * *

Related by context. Frequent words. (Click for all words.) 64 PCa 63 biochemical recurrence 62 CaP 61 progesterone receptor 61 neoplasms 61 papillary 61 squamous 61 histologic 61 breast carcinoma 60 cystectomy 60 lymph node metastases 60 immunohistochemical 60 transurethral resection 60 serum PSA 60 distant metastasis 60 statistically significant p = 60 mRNA expression 60 adenocarcinomas 60 confidence interval #.#-#.# 59 micrometastases 59 D dimer 59 mediastinal 59 neoadjuvant 59 histopathological 59 serum concentrations 59 malignant lesions 59 pheochromocytoma 59 stenoses 59 metastatic renal cell carcinoma 59 cerebrospinal fluid CSF 59 lymph node involvement 59 EpCAM 59 prostatic 58 tumor recurrence 58 neoplastic 58 EBRT 58 P = .# 58 biodistribution 58 achieved statistical significance 58 androgen independent 58 haematological 57 chemoradiotherapy 57 HSCT 57 mRCC 57 estrogen receptor ER 57 fine needle aspiration 57 resected 57 colorectal adenomas 57 KRAS wild 57 univariate analysis 57 neoadjuvant chemotherapy 57 peripheral blood mononuclear 57 distant metastases 57 neoadjuvant therapy 57 metastatic lesions 57 prognostic marker 57 endometrial 57 neoplasia 57 superficial bladder cancer 57 splenic 57 Lenalidomide 57 adjuvant therapy 57 liposomal formulation 57 K ras 57 sensitivity specificity 57 carcinoid tumors 57 NGAL 56 Preoperative 56 tumor lysis syndrome 56 prognostic factor 56 pathologic 56 metastatic liver 56 parathyroid 56 multivariate analyzes 56 neoplasm 56 HER2/neu 56 Prognostic 56 hematuria 56 prespecified 56 rheumatoid factor 56 morphologic 56 physiologically relevant 56 gastrointestinal stromal tumors 56 prostate biopsy 56 adenoma 56 thromboembolic 56 decitabine 56 EGFR mutation 56 Secondary endpoints include 56 allogeneic stem cell 56 HER2 negative 55 Irinotecan 55 platelet reactivity 55 antiangiogenic 55 relapsed refractory 55 liver metastases 55 grade gliomas 55 univariate 55 nab paclitaxel 55 daunorubicin 55 sonographic

Back to home page